Navigation Links
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Date:12/11/2007

a nephrotoxic agent. ATRIPLA may cause fetal harm when administered during the first trimester to a pregnant woman. Women should not become pregnant or breast-feed while taking ATRIPLA. Barrier contraception must always be used in combination with other methods of contraception (eg, oral or other hormonal contraceptives). If the patient becomes pregnant while taking ATRIPLA, she should be apprised of the potential harm to the fetus.

Mild-to-moderate rash is a common side effect of efavirenz. In controlled clinical trials, 26% of patients treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control groups. ATRIPLA should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Skin discoloration, associated with emtricitabine, may also occur.

Liver enzymes should be monitored in patients with known or suspected hepatitis B or C and when ATRIPLA is administered with ritonavir or other medications associated with liver toxicity.

Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF.

Use ATRIPLA with caution in patients with a history of seizures. Convulsions have been observed in patients receiving efavirenz, generally in the presence of known medical history of seizures.

Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including the components of ATRIPLA.

Saquinavir should not be used as the only protease inhibitor in combination with ATRIPLA.

Coadministration of ATRIPLA and atazanavir is not recommended due to concerns regarding decreased atazanavir concentrations. Atazanavir and lopinavir/rito
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
3. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
(Date:5/23/2013)... PARIS , May 23, 2013 ... (NYSE MKT: NSPR), the leader in embolic protection ... MASTER (MGuard for Acute ST Elevation Reperfusion) trial ... outperformed bare metal and drug eluting stents in ... (STEMI) patients.  Results from the trial were presented ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
(Date:5/23/2013)... Dr. Garber's Natural Solutions is ... now available at Whole Foods Laguna Niguel, 23932 Aliso ... of natural biotherapy formulas continues to expand its' presence ... Brandstorm HBC (Los Angeles, CA), the line of remedies ... and Arizona, as well as Lassen's Markets in California, ...
(Date:5/23/2013)... May 23, 2013 On May 23, Voices ... and advocacy, commends Salem High School senior Max Merget for ... , According to a Patch.com article, Max Merget ... anaplastic ependymoma -- a large malignant tumor in the dominant, ... underwent surgery but the tumor came back a year later ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Brad Schmett, ... announced that the already sizzling Palm Springs area ... thanks to the immense popularity of the Annual Memorial ... on Monday, May 27, 2013. , Culminating the festive ... of programs and events along with flight exhibitions. However, ...
(Date:5/23/2013)... May 23, 2013 After working continuously ... beta testing regimes, Shopping Cart Elite officially ... Redsandmotorsports.com is an Arizona based online store retailing in ... , “Addition of new stores to our clientele has ... Cart Elite, Igor Soshkin. “We are extremely elated with ...
(Date:5/23/2013)... Texas (PRWEB) May 23, 2013 ... their daily routines, Walkingspree is pleased to announce ... with Fitbit pedometer devices. This new upgrade automatically ... dashboard members use to track their company’s team ... chart calories and fat burned. , Walkingspree also ...
Breaking Medicine News(10 mins):Health News:Dr. Garber's Natural Solutions Now Available at Whole Foods Market, Laguna Niguel, CA 2Health News:Voices Against Brain Cancer Commends Young Man for Raising Money for Brain Cancer Despite Fighting His Own Battle 2Health News:Annual Memorial Day Flower Drop Honors Veterans in Palm Springs California by Brad Schmett 2Health News:Shopping Cart Software Provider, Shopping Cart Elite Officially Announces the Launch Of Redsandmotorsports.com 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 3
... Va., Sept. 30 Military Officers Association ... Jr., USN (Ret), pulled no punches in expressing MOAA,s ... raising hospital inpatient copays by $110 per day for retired ... "We,re shocked and extremely disappointed that there would be any ...
... Anchor Bay Entertainment, the successful distributor of independent ... with Susan G. Komen for the Cure(®) in the ... months, Anchor Bay Entertainment will donate $1 for each ... well as develop specialized promotions for the campaign to ...
... ... AllerQuest, LLC, are pleased to announce the return of PRE-PEN® penicillin allergy skin testing ... has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN®. ... Round Rock, TX ...
... benefit when therapy goes to more than just severe ... -- Pregnant women who receive treatment for the mildest ... intervention, self-monitoring of blood glucose levels and possibly insulin ... complications or develop preeclampsia or high blood pressure during ...
... ... Investor and New England Patriots President Jonathan Kraft , ... Boston, MA (Vocus) September 30, 2009 -- The Boston biotechnology industry ... Boston Biotech R&D Conference on October 27, 2009 at Harvard Medical School. , , ...
... Sept. 30 Most American children don,t see their family ... later than is recommended by both dental and medical professionals. ... of American children,s oral health, conducted on behalf of Delta ... Dental commissioned the survey to gain greater knowledge about the ...
Cached Medicine News:Health News:MOAA Decries 21% TRICARE Inpatient Copay Hike 2Health News:Anchor Bay Entertainment Joins Forces With Susan G. Komen for the Cure(R) in the Fight Against Breast Cancer 2Health News:Anchor Bay Entertainment Joins Forces With Susan G. Komen for the Cure(R) in the Fight Against Breast Cancer 3Health News:FDA Approves PRE-PEN Penicillin Allergy Test 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 3Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Health News:Delayed First Visit to Dentist Can Affect Children's Lifelong Oral Health 2
... (TSH) is a 32 kDa glycoprotein secreted ... pituitary gland [1]. The structure of human ... pituitary and placental gonadotropins, consisting of an ... these hormones and a unique beta-subunit, which ...
... Thyroxine (T4) is the primary active hormone ... thyroid gland [1]. T4 is synthesized via ... trapping by the follicular cells, (ii) iodination ... leading to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine ...
... is produced primarily by 5-monodeioination of thyroxine ... gland, T3 production occurs at a rate ... T4. Release of T3 from the thyroid ... as compared to 80-100 micrograms/day for T4. ...
... Insulin-like growth factor binding protein-3 (IGFBP-3) is the ... postnatal serum, as a component of the ~150 ... a molecule of IGF-I or IGF-II and ALS, ... actions of the IGFs. The molar concentration of ...
Medicine Products: